Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy
Trial Parameters
Brief Summary
This study is a multicenter, randomized controlled clinical trial to explore the preliminary efficacy and safety of treatment response adapted hybrid radiotherapy (LDRT and SBRT) in the first-line treatment of immunotherapy combined with chemotherapy for advanced driver-gene negative NSCLC, and to provide new ideas for the comprehensive treatment of advanced NSCLC
Eligibility Criteria
Inclusion Criteria: * ECOG functional status score was 0-1. * Histologically confirmed stage IV primary NSCLC; * Genetic testing showed that the common driver genes including EGFR, ALK and ROS-1 were negative; * Patients with brain metastases were eligible if they were neurologically asymptomatic and had stable disease without receiving systemic glucocorticoids; * According to the investigator's judgment, the patient does not need to receive palliative radiotherapy for any site at present; * Male/female of childbearing age agreed to use contraception (surgical ligation or oral contraceptive/intrauterine device plus condom) during the trial; * Life expectancy ≥3 months; * One week before enrollment, the organ function level met the following criteria: ① Bone marrow function: hemoglobin ≥80g/L, white blood cell count ≥4.0\*10\^9/L or neutrophil count ≥1.5\*10\^9/L, platelet count ≥100\*10\^9/L; ② Liver: serum total bilirubin level ≤1.5 times upper limit of normal, direct bilirubin level